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Abstract
Background: Despite the enormous global burden of tuberculosis (TB), conventional approaches to diagnosis continue to
rely on tests that have major drawbacks. The improvement of TB diagnostics relies, not only on good biomarkers, but also
upon accurate detection methodologies. The 10-kDa culture filtrate protein (CFP-10) and the 6-kDa early secreted antigen
target (ESAT-6) are potent T-cell antigens that are recognised by over 70% of TB patients. Aptamers, a novel sensitive and
specific class of detection molecules, has hitherto, not been raised to these relatively TB-specific antigens.
Methods: DNA aptamers that bind to the CFP-10.ESAT-6 heterodimer were isolated. To assess their affinity and specificity to
the heterodimer, aptamers were screened using an enzyme-linked oligonucleotide assay (ELONA). One suitable aptamer
was evaluated by ELONA using sputum samples obtained from 20 TB patients and 48 control patients (those with latent TB
infection, symptomatic non TB patients, and healthy laboratory volunteers). Culture positivity for Mycobacterium tuberculosis
(Mtb) served as the reference standard. Accuracy and cut-points were evaluated using ROC curve analysis.
Results: Twenty-four out of the 66 aptamers that were isolated bound significantly (p,0.05) to the CFP-10.ESAT-6
heterodimer and six were further evaluated. Their dissociation constant (KD) values were in the nanomolar range. One
aptamer, designated CSIR 2.11, was evaluated using sputum samples. CSIR 2.11 had sensitivity and specificity of 100% and
68.75% using Youden’s index and 35% and 95%, respectively, using a rule-in cut-point.
Conclusion: This preliminary proof-of-concept study suggests that a diagnosis of active TB using anti-CFP-10.ESAT-6
aptamers applied to human sputum samples is feasible.
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Introduction
TB is a major fatal infectious disease. The current World Health
Organization (WHO) figures estimate a worldwide TB incidence
of 8.8 million per year and 1.45 million deaths annually [1]. This
statistic is compounded by the emergence of drug-resistant strains
of TB [2,3,4] and co-infections with human immunodeficiency
virus (HIV) [5].
Timely diagnosis of active pulmonary TB cases is important for
the control of the disease. Despite the enormous burden of TB,
conventional approaches to diagnosis used today rely on tests that
have major drawbacks. The current gold standard for diagnosing
TB is smear microscopy and culture. The major drawback of
sputum smear microscopy is its poor sensitivity 2 estimated at
50% [6,7]. The culture method is the most sensitive, however, it is
more expensive than microscopy, requires up to eight weeks for
the isolation of Mycobacterium tuberculosis (Mtb), and requires a high
standard of technical competence [8]. Other methods available for
diagnosing active TB include the lipoarabinomannan (LAM)
antigen-detection assay [9,10] and, more recently, a fully auto-
mated polymerase chain reaction (PCR)-based molecular test
called GeneXpertH. The GeneXpertH has advantages in that it is
rapid and little training is required. However, the drawback is that
the test is currently expensive and not a point-of-care tool.
Furthermore, the sensitivity of the GeneXpertH in the South
African setting was found to be suboptimal in smear-negative,
HIV-infected patients [11].
Accurate diagnosis of TB requires reliable biomarkers as targets
of detection. Two Mtb proteins that have attracted attention as
desirable targets for new TB drugs and diagnostics are CFP-10
and ESAT-6 [12,13,14,15]. The CFP-10 protein, encoded by the
Rv3874 (esxB) gene, and the ESAT-6 protein, encoded by the
Rv3875 (esxA) gene, can interact in vitro to form a tight 1:1
heterodimer [16,17]. These two proteins are potent T-cell antigens
recognised by over 70% of tuberculosis patients and are thus good
TB biomarkers [18,19,20]. Moreover, CFP-10 and ESAT-6 are
not present in many nontuberculous mycobacteria and in the
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) vaccine
[5,18,19]. A recent study reported on the use of antibodies to
detect the two proteins in clinical specimens with a sensitivity of
81.6% and 95.4% for CFP-10 and ESAT-6, respectively, and
a specificity of 92.2% and 100% for the two proteins, respectively
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[20]. This data bodes well for a diagnostic tool that detects the
antigens in clinical specimens. However, the use of antibodies as
detection reagents has some limitations, which can be circum-
vented by aptamers.
Aptamers, by virtue of their high specificity and high sensitivity,
could serve as tools for the early and specific detection of active TB
and meet the ASSURED (Affordable, Sensitive, Specific, User-
friendly, Rapid and robust, Equipment-free, and Deliverable to
the end user) diagnostic guidelines recommended by WHO for
developing countries [21]. The isolation of aptamers, with the
capacity to recognise virtually any class of target molecule with
high affinity and specificity, has been made possible by the
development of the systematic evolution of ligands by exponential
enrichment (SELEX) process [22,23,24]. Since aptamers can be
produced using chemical synthesis or by PCR, the cost of
producing aptamers is 10–50 times less than those for producing
antibodies [25]. Aptamers have been raised against a wide variety
of targets, from small human molecules and viral proteins to whole
microorganisms [26].
Single-stranded DNA (ssDNA) aptamers are usually used for
diagnostics due to the greater inherent stability of DNA and low
cost of production compared to RNA aptamers. Examples include
aptamers that detect thrombin, adenosine and cocaine
[27,28,29,30,31]. Aptamers have also been raised against (1–3)-
b-D-glucans, which were the first aptamers developed for the
detection of a biotoxin in environmental respiratory diseases [25].
TB-specific aptamers include ssDNA aptamers against Mtb
polyphosphate kinase 2 (PPK2) [32], as well as aptamers against
the whole Mtb bacterium [33]. Furthermore, aptamers against
MPT64 were the first ones raised against Mtb [34], but this
antigen lacks the sensitivity of more potent antigens like ESAT-6
and CFP-10. To date, however, aptamers have not been raised
against the immuno-dominant antigens CFP-10 and ESAT-6, or
the CFP-10.ESAT-6 heterodimer.
The aim of this study was therefore to isolate ssDNA aptamers
against the CFP-10.ESAT-6 heterodimer and test the ability of




Approval for the use of sputum samples for this study was
obtained from the University of Cape Town, Health Science
Faculty Research Ethics Committee (Ethics number: REC REF:
421/2006). Written consent was received from patients whose
sputum is used in the study.
Expression and Purification of Recombinant CFP-10 and
ESAT-6 Proteins
E. coli BL21(DE3) cells (Novagen) were transformed with the T7
promoter-based expression plasmids pMRLB46 or pMRLB7 for
expression of full-length histidine (His)-tagged CFP-10 and ESAT-
6 proteins, respectively. Expression of the recombinant proteins
was induced in mid-exponential phase cultures, by addition of
isopropyl-b-D-galactopyranoside (IPTG). For cultures expressing
CFP-10, the cells were harvested 4 h after induction, whereas for
ESAT-6, the induced cultures were incubated overnight at 25uC
before the cells were harvested. The respective cell pellets were
suspended in 10 ml of Buffer A (6 M urea, 25 mM Tris-HCl,
200 mM NaCl, 10 mM imidazole, pH 7.4). The cells were
disrupted by sonication (Bandelin Sonoplus HD2070), after which
the lysate was clarified by centrifugation (14,000 rpm for 15 min
at 4uC). For CFP-10, the supernatant (cytosol fraction) was loaded
onto a nickel-nitrilotriacetic acid (Ni-NTA) column, which had
been pre-equilibrated with Buffer A. The urea was removed by six
washes with 10 ml of Buffer A, in which the urea concentration
was decreased from 6 M to 1 M, followed by two washes with
20 ml of Buffer B (25 mM Tris-HCl, 200 mM NaCl, 10 mM
imidazole, pH 7.4). Finally, CFP-10 was eluted in a single step
with 10 ml of Buffer B containing 300 mM imidazole. ESAT-6
was purified from the cytosol fraction using a protocol similar to
that used for the purification of CFP-10, except that the Ni-NTA
column was washed successively with 20 ml of Buffer B containing
40 mM and 50 mM imidiazole, respectively, before elution of the
ESAT-6 protein in 300 mM imidazole. The purified CFP-10 and
ESAT-6 proteins were resolved by 17% SDS-PAGE and
electroblotted onto HybondTM-ECL nitrocellulose membranes
(GE Healthcare) for immunoblot analysis using either an anti-
CFP-10 polyclonal antibody (provided by Megan Lucas, Colorado
State University) or an anti-ESAT-6 monoclonal antibody (Santa
Cruz Biotechnology).
Complex Formation of CFP-10 and ESAT-6
Equimolar amounts of CFP-10 and ESAT-6 were mixed in
a phosphate buffer at room temperature, as described previously
[17]. Complex formation of CFP-10 and ESAT-6 was confirmed
by native PAGE analysis and surface plasmon resonance (SPR)
using a BIAcoreH 3000 instrument.
Isolation of Aptamers against the CFP-10.ESAT-6
Heterodimer
A 90-mer ssDNA randomised at 49 nucleotide positions and
flanked by constant regions was custom-synthesised by Integrated
DNA Technologies (CA, USA). The constant regions allowed for
primer annealing and PCR amplification. The primer sequences
were 59-GCCTGTTGTGAGCCTCCTAAC-39 (forward primer)
and 59- GGGAGACAAGAATAAGCATG-39 (reverse primer
modified with either the T7 promoter region TAATACGACT-
CACTATA, or a phosphate at the 59 end). The library used was
59-GCCTGTTGTGAGCCTCCTAAC(N49)CATGCT-
TATTCTTGTCTCCC-39. The selection of aptamers was done
according to the SELEX protocol, as described previously [35].
Briefly, before the first round of selection, the ssDNA library was
incubated with a nitrocellulose membrane to remove any
membrane-binders. The ssDNA was refolded by initial denatur-
ation at 95uC for 10 min, followed by immediate cooling on ice for
5 min and then incubated at room temperature for 5 min in
HMCKN binding buffer (20 mM HEPES, 2 mM MgCl2,
2 mM CaCl2, 2 mM KCl and 150 mM NaCl, pH 7.4). This
was then incubated with 1590 nM of CFP-10.ESAT-6 hetero-
dimer for 1 hour at 37uC. The ssDNA-protein mixture was passed
through a nitrocellulose membrane. Non-specifically bound
ssDNA was removed with two washes of HMCKN binding
buffer, whereas ssDNA bound to the heterodimer was recovered
with a 7 M urea buffer and purified for use in the next round of
selection.
After the first round of selection, PCR was used to amplify the
selected ssDNA into double stranded DNA (dsDNA). All PCR
procedures were carried out under the following conditions: 95uC
for 3 min, 8–12 cycles at 95uC for 1 min, 54uC for 1 min and
72uC for 90 sec, followed by a final extension at 72uC for 8 min.
After the PCR, two different methods were used to generate
ssDNA from the dsDNA. The first method used the dsDNA as
a template for in vitro transcription to obtain RNA. The RNA was
treated with DNase I, purified and precipitated. It was then used
as the template in an RT-PCR to obtain cDNA. The cDNA-RNA
mixture was treated with a 1 M NaOH, 0.5 M EDTA buffer to
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hydrolyse the RNA. The cDNA was purified and used as template
for the next round of selection (this method is referred to as ‘T7-
based SELEX’). The second method used to generate ssDNA was
by digestion of the dsDNA with lambda exonuclease; this was
done by including a phosphate on the 59 end of the reverse primer.
The dsDNA was purified and treated with lambda exonuclease
(New England Biolabs), resulting in the degradation of the reverse
strand with the phosphate modification [36]. The resulting ssDNA
was then purified and used as template for the next round of
selection. This method is referred to as ‘exonuclease-based
SELEX’.
To minimise the possibility of selecting aptamers that bind to
the nitrocellulose partitioning membrane, the aptamer pool from
the fifth T7-based and third exonuclease-based SELEX rounds
were respectively subjected to a counter-selection against the
nitrocellulose partitioning membrane. The pools recovered after
counter-selections were put through final SELEX rounds (i.e. sixth
– T7-based SELEX and fourth – exonuclease-based SELEX,
respectively). In this last round, both pools of ssDNA were
amplified with the phosphate-modified reverse primer and the
resultant PCR products were cloned into the pGEM-T Easy
vector (Promega). Nucleotide sequencing of each individual clone
was performed by Inqaba Biotechnical Industries (Pretoria, South
Africa) using universal pUC/M13 sequencing primers.
Binding Assay of ssDNA Aptamers by ELONA
Unique aptamers identified by nucleotide sequencing were
tested for their binding ability to the CFP-10.ESAT-6 hetero-
dimer, as well as the individual monomers (CFP-10 and ESAT-6)
using an ELONA [37]. Briefly, each ssDNA aptamer was
prepared with a biotinylated forward primer using the exonuclease
method as described above. Protein concentrations were de-
termined by a Bicinchoninic acid protein assay (BCA) so that wells
could be coated with equimolar amounts of the heterodimer or
with the respective monomers. The 96-well microtitre plates were
coated with 500 ng of the proteins in 100 ml of NaCO3 buffer
overnight at 4uC. Following blocking with a 5% fat-free milk
solution for 1 hour at 4uC, the wells were washed four times with
TBS buffer. Biotinylated aptamers (500 nM) were added to each
well and incubated for 2 hours at room temperature. The wells
were washed four times with TBS buffer. Streptavidin-horseradish
peroxidase conjugate (KPL) was diluted 1:15 000 in TBS buffer,
and 100 ml was applied to each well. The plates were incubated for
2 hours at 37uC and washed again as described above. Then,
50 ml of Turbo-3,39,5,59-tetramethylbenzidine (TMB, Pierce) was
added to each well and incubated for 15 min at 37uC. The
reaction was quenched by addition of 50 ml of 1 M H2SO4, and
the protein-bound aptamer-streptavidin complexes were quanti-
fied by determining the absorbance at 450 nm using a MultiSkan
Go plate reader (Thermo Scientific).
Aptamer-antibody Competition Assay
The aptamer-antibody competition binding was performed
using the ELONA method described above with minor modifica-
tions. An ESAT-6 monoclonal antibody (Santa Cruz Biotechnol-
ogy) was coated onto a 96-well microtitre plate overnight, followed
by blocking and binding of the heterodimer. The biotinylated
aptamer was then added, followed by the HRP-conjugated
streptavidin. The data obtained from the competition assay was
compared to that from the affinity binding assay to identify
differences in binding capacity of the aptamers in the presence of
the antibody. Although the competition and binding assays were
performed on different plates, the positive control, CFP-10.ESAT-
6 heterodimer and one aptamer, were tested on both plates with
similar results. Data from one plate was normalised to the control
of that plate, and compared to data from the other plate.
Determination of the Dissociation Constant (KD) of
Individual ssDNA Aptamers
To determine the affinity of the ssDNA aptamers to CFP-10
kinetic studies were conducted using a BIAcoreH 3000 instrument.
All four flow cells on a CM5 chip (BIAcore, Separations Scientific)
were activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodii-
mide (EDC) and N-hydroxysuccinimide (NHS) (BIAcore, Separa-
tions Scientific). CFP-10 was coupled to three of the four flow cells
and any remaining carboxy site on the chip surface was blocked
using 1 M ethanolamine-HCl. The ssDNA aptamer (at concen-
trations 500 nM, 250 nM, 125 nM, 62 nM, and 31 nM) was
injected over all activated flow cells at a flow rate of 10 ml/min for
5 min with a dissociation time of 10 min. This was repeated for
each of the six selected ssDNA aptamers. The flow cell that did not
have CFP-10 was used as the control to subtract non-specific
binding. The evaluation was done using BiaEvaluation Software
(BIAcore) to determine the KD values for each aptamer.
Determination of the Effect of Aptamer Folding on
Target Binding
To assess the downstream application of one ssDNA aptamer,
namely CSIR 2.11, as a potential detection reagent for TB, we
determined whether or not the aptamer needed to be refolded to
retain its functionality. One batch of CSIR 2.11 was folded as
described earlier, and the other batch of CSIR 2.11 was used
directly after thawing. An ELONA was performed with both
batches of CSIR 2.11 to determine binding to the CFP-10
monomer.
Specificity Testing
To determine specificity, all six aptamers were tested in an
ELONA for binding to lysates of different bacteria found in the
oral cavity, namely: Pseudomonas aeruginosa, Streptococcus pyrogenes,
Staphylococcus aureus, Mycobacterium smegmatis, Mycobacterium bovis
BCG, Mycobacterium tuberculosis, and Corynebacterium xerosis. Lysates
were obtained by bead-beating 200 ml of each culture. A
bicinchoninic acid (BCA) protein assay was used to determine
the total protein concentration of the prepared lysates. An equal
amount of total protein was then coated onto 96-well microtitre
plates using the Mycobacterium tuberculosis lysate as the positive
control.
Antigen Detection in Sputum Samples
To determine the use of the ssDNA aptamers as detection
reagents, one suitable ssDNA aptamer was tested in a small case
controlled study. Forty sputum samples that have been well
characterised were obtained from the Lung Infection and
Immunity Unit, Groote Schuur Hospital and the University of
Cape Town (South Africa), were used for the clinical study. A
further fifteen apparently healthy volunteers working at the CSIR
donated one to two sputum samples for testing (Figure 1). All
sputum samples obtained were liquefied in a 0.1% dithiothreitol
(DTT) solution. The sputum samples were bound to a 96-well
microtitre plate in NaHCO3 buffer and left overnight at 4uC. An
ELONA was performed to determine whether the aptamer was
able to detect CFP-10 in sputum samples using CSIR 2.11. A
specificity and sensitivity comparison, by means of an ELONA,
between CSIR 2.11 and CSIR 2.21 was performed using a small
subset of samples (28 sputum samples). CSIR 3.13, which is an
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aptamer selected from the same parental library but against an
unrelated target was used as a negative control.
Statistical Analysis
For binding and aptamer-antibody competition assays, each
plate had an aptamer alone control, which was averaged, before
subtracting the average from each well to eliminate background
noise. Each aptamer or aptamer-antibody combination was tested
in triplicate, in two separate experiments. The repeats were
averaged and the standard deviation calculated. Statistical
significance was calculated relative to the aptamer alone control
using a two-tailed Student t-test. For the kinetic studies the
BIAevaluation software calculates a Chi2 value for the dissociation
constant. For the small case controlled study each sputum sample
was tested in triplicate. The results were averaged and the
standard deviation was calculated for each sputum sample. Each
experiment was repeated twice to determine repeatability of the
assay by calculating the coefficient of variance. The diagnostic
performance of the assay was evaluated using ROC curve analysis
(SigmaPlot 12.0, Statsoft, Inc.; GraphPad Prism 5.04, GraphPad
Software, Inc.) and cut-points were determined based on Youden’s
index, as well as the rule-in method.
Results
Protein Expression, Purification and Heterodimer
Formation
The His-tagged CFP-10 protein was purified from the soluble
fraction of induced cell lysates using nickel affinity chromatogra-
phy. SDS-PAGE analysis showed the presence of CFP-10 without
any visible contaminants (Figure S1A), and the purified protein
was shown by immunoblot analysis to react with an anti-CFP-10
polyclonal antibody (Figure S1B). Typically, 2.4 mg of monomeric
CFP-10 was obtained from 1 l of bacterial culture. In contrast to
CFP-10, the ESAT-6 protein is expressed in E. coli predominantly
as an insoluble protein and solubilisation of the protein requires
exposure to a strong chaotropic agent such as guanidine-HCl or
urea at concentrations from 6–8 M [15,17]. Here, we adopted
a strategy aimed at limiting in vivo aggregation of the recombinant
protein by growing the IPTG-induced bacterial culture overnight
at a reduced temperature (25uC). Using this approach, the ESAT-
6 protein was localised to the soluble fraction of the induced cell
lysate. This finding is in agreement with other reports regarding
expression of different antigens of M. tuberculosis, which indicated
that lowering of the growth temperature leads to enhanced
solubility [15,38]. Following purification, SDS-PAGE analysis of
the eluate indicated that it contained the ESAT-6 protein (Figure
S1C), which reacted specifically with an anti-ESAT-6 monoclonal
antibody in immunoblot analysis (Figure S1D). The purification
procedure yielded 1.3 mg of monomeric ESAT-6 from 4 l of
bacterial culture.
To determine whether the recombinant CFP-10 and ESAT-6
proteins were capable of interacting and forming a heterodimer,
the respective purified proteins were mixed and the mixture was
analysed by native PAGE. The results indicated that the protein
complex migrated as a single band in the presence of excess
monomeric CFP-10 (Figure S2A). Additionally we used surface
plasmon resonance (SPR) assays to corroborate the interaction
between the CFP-10 and ESAT-6 proteins. Since the ESAT-6
protein did not bind to the surface of a CM5 sensor chip in the
absence of immobilized CFP-10 protein, the results provide
supporting evidence for specificity in the interaction between the
two recombinant proteins (Figure S2B).
Isolation of Aptamers against the CFP-10.ESAT-6
Heterodimer
To isolate aptamers against the CFP-10.ESAT-6 heterodimer,
a modified SELEX protocol was followed [35]. The starting
Figure 1. Study flow diagram. Study plan and patient categorisation of the 68 participants in active (definite) TB, latent TB, TB negative and
healthy donors that were evaluated in the proof-of-principle study.
doi:10.1371/journal.pone.0046862.g001
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library contained a random region of 49 nucleotides, and
a complexity of 1014 unique sequences was used for the first
round of selection. Two methods of selection were used to
maximise the number of aptamers that could be isolated. The T7-
based SELEX resulted in an enrichment of 54.7% after six rounds
of selection and the exonuclease-based SELEX had an enrichment
of 68% after four rounds of selection (Figure 2). Counter-
selections, to eliminate non-specific binders, were performed after
round 3 and 5 for the exonuclease-based and T7-based SELEX,
respectively. After selection, the ssDNA pools were purified and
cloned. A total of 104 clones were obtained and subjected to
nucleotide sequencing. Sequence analysis indicated the presence of
66 unique clones that comprised of five obtained from the
exonuclease-based SELEX method and the remainder were
obtained using the T7-based SELEX method. Aptamers obtained
from both the exonuclease- and the T7-based SELEX methods
were used for further studies.
Binding of ssDNA Aptamers to the CFP-10.ESAT-6
Heterodimer
To determine the binding ability of individual aptamers to the
CFP-10.ESAT-6 heterodimer, an ELONA was used in which
biotinylated aptamers were added to immobilised heterodimer.
Out of the 66 biotinylated ssDNA aptamers screened against the
CFP-10.ESAT-6 heterodimer, 24 bound significantly (p,0.05) to
the heterodimer. Of these 24 aptamers, six aptamers that
displayed the highest OD450 readings were chosen for further
analysis (Figure 3).
Aptamer-antibody Competition Binding Assays of
Individual ssDNA Aptamers
An aptamer-antibody competition assay was performed to
determine whether the aptamers could be used in the presence of
the anti-ESAT-6 monoclonal antibody. This is important for
downstream assays that could involve a sandwich assay using the
aptamers. Binding of some ssDNA aptamers such as CSIR 2.9,
CSIR 2.15 and CSIR 2.21 was abrogated by the presence of anti-
ESAT-6 monoclonal antibody, whereas binding of others such as
CSIR 2.11 and CSIR 2.19 was unaffected by the presence of the
ESAT-6 monoclonal antibody (Figure 4). This data suggests that
in the case of abrogated aptamer binding the presence of the
ESAT-6 monoclonal antibody may have caused allosteric effects,
thereby blocking binding sites on the heterodimer recognised by
the aptamers.
Binding of Individual ssDNA Aptamers to Protein
Monomers
It was established that the ssDNA aptamers could bind to the
CFP-10.ESAT-6 heterodimer; however, it was not yet known
whether the aptamers bound preferentially to one of the two
monomers (i.e. CFP-10 or ESAT-6) or only bind to the
heterodimer. Thus, the binding of the six selected aptamers to
CFP-10 and ESAT-6 monomers was determined using ELONA.
Interestingly, although the aptamers were isolated against the
heterodimer, all six of the selected aptamers recognised the CFP-
10 monomer, in addition to the CFP-10.ESAT-6 heterodimer,
but none of the aptamers recognised the ESAT-6 monomer
(Figure 5).
To confirm that the aptamers could be chemically synthesised
and not affect their binding abilities, the six aptamers were
synthesised by solid phase with a biotin modification. The binding
of these aptamers to the CFP-10.ESAT-6 heterodimer, as well as
CFP-10 and ESAT-6 was subsequently repeated. There was no
significant (p.0.05) difference in the binding affinity between the
in vitro- and the solid phase-synthesised aptamers (Figure S3). Both
the in vitro and chemically-synthesised aptamers showed consistent
results in that none of the aptamers recognised the ESAT-6
monomer, while they were able to bind to the CFP-10.ESAT-6
heterodimer and the CFP-10 monomer.
Dissociation Constant (KD) of Individual ssDNA Aptamers
To determine the binding kinetics of the aptamers, CFP-10 was
amine-coupled onto a CM5 chip, followed by the injection of the
aptamers to obtain dissociation equilibrium constant (KD) values
for each aptamer. All aptamers gave KD values in the lower
nanomolar range. CSIR 2.19 had the lowest KD of 1.660.5 nM,
CSIR 2.11 had a KD of 861.07 nM and CSIR 2.2 had
comparatively the highest KD of 21.564.3 nM (Figure 6). The
Chi2 values for the kinetic studies ranged between 0.015 and 1.09.
Chi2 values below 2 illustrate a good fit of data to the 1:1
Langmuir model; indicating tight affinity of the aptamers to the
CFP-10 monomer.
Figure 2. Percentage recovery of ssDNA using different SELEX methods. Both exonuclease- and T7-based methods were used to generate
ssDNA, and counter-selection was preformed after round 3 (exonuclease-based SELEX) and 5 (T7-based SELEX).
doi:10.1371/journal.pone.0046862.g002
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Effect of Aptamer Folding on Target Binding
CSIR 2.11 was chosen for further studies as it was unaffected in
the aptamer-antibody competition assay. For aptamers to be used
as detection reagents, they must be stable. Thus, we determined
whether a refolding step was necessary for the aptamer to bind to
the CFP-10 protein. One batch of CSIR 2.11 was folded as
described in the methods and another batch of CSIR 2.11 was
Figure 3. Binding affinity of ssDNA aptamers to the CFP-10.ESAT-6 heterodimer. Results are shown for a selection of biotinylated ssDNA
aptamers. Biotinylated ssDNA aptamers that bound significantly (p,0.05) to the heterodimer in an ELONA assay are denoted by the asterisks. Data
are presented as means 6 standard deviation of the mean.
doi:10.1371/journal.pone.0046862.g003
Figure 4. Aptamer-antibody competition binding assay. An ELONA was used to determine binding of selected anti-CFP-10.ESAT-6
biotinylated ssDNA aptamers to the heterodimer in the presence (striped bar) or absence (solid white) of anti-ESAT-6 monoclonal antibody. Data are
presented as means 6 standard deviations of the mean.
doi:10.1371/journal.pone.0046862.g004
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used directly after thawing. The results showed that the aptamer
can be used directly after thawing without the refolding step
(Figure S4). This data is useful for the application of CSIR 2.11 as
a detection reagent. It suggests that the aptamer retains a stable
structure for prolonged periods without requiring heating and
cooling to fold correctly in order for it to bind to CFP-10.
Specificity Testing
To determine the specificity of the ssDNA aptamers, lysates
were prepared from bacteria inhabiting the oral cavity and
evaluated for binding to the aptamers in an ELONA. The six
tested aptamers had variable binding, although all aptamers were
able to recognise Mycobacterium tuberculosis lysates and none of the
aptamers were able to bind to the lysates of S. pyogenes or C. xerosis
(Table 1, Figure S5). M. smegmatis, M. bovis BCG and S. aureus
lysates were recognised by five of the six aptamers, whereas the
P. aeruginosa lysate was recognised by three of the six aptamers
(Table 1, Figure S5).
Antigen Detection in Sputum Samples
To evaluate the aptamers for detecting TB infection using
clinical sputum samples, the utility of CSIR 2.11 was tested in 68
sputum samples in an ELONA assay. Based on the ROC curve
analysis with a 99% confidence interval, the study showed that in
86% (p,0.0001) of randomly selected cases, a TB-positive
individual has a test value (OD450) higher than a TB-negative
individual. In this study, the cut-point for positive readings based
on the ROC curve analysis using the Youden’s index was
OD450 = 0.2. Using this cut-off, the assay has a specificity of
68.75% and sensitivity of 100% (Table 2, Figure S6). However,
when a rule-in disease cut-point is considered the specificity is set
at 95% and the sensitivity decreases to 35% (Table 2, Figure S6).
This decrease is due to one healthy donor and two TB-negative
samples that had high positive readings. As expected, CSIR 3.13,
which was used as a negative control, did not detect TB in the
sputum samples (Figure S7). The coefficient of variance was
ranged between 2 and 10%, indicating the repeatability of the test.
A more specific aptamer, CSIR 2.21, was compared to CSIR 2.11
using 28 sputum samples. The data shows that the two aptamers
were comparable with a specificity of 85% and sensitivity of 10%
using a rule-in disease cut-point, and a specificity of 60% and
sensitivity of 65% using the Youden’s index (Figure S8).
Discussion
We isolated aptamers against the CFP-10.ESAT-6 heterodimer
to be used as potential TB detection reagents. In a small case
controlled study, the aptamer-based assay had a sensitivity of
100% and a specificity of 68.75% using Youden’s index, which is
encouraging for development of the aptamers as detection
reagents for active TB.
It was interesting to note that even though the aptamers were
raised against the heterodimer, all aptamers displayed a preference
for one of the monomers, namely CFP-10, over the heterodimer.
This is a unique situation and had not been previously observed
when RNA aptamers were raised against the human interleukin-
17A/F heterodimer [39]. This could be due to RNA aptamers
forming more stable secondary and tertiary structures than ssDNA
aptamers. Alternatively, the ESAT-6 binding sites may not be
accessible to the aptamers when ESAT-6 is bound to CFP-10.
Aptamers are known to bind preferentially to functional parts of
proteins [40,41,42,43]. The flexible C terminus of CFP-10 has
been shown to be involved in interactions with cell surfaces.
Indeed, deletion of the 87 amino acids at the C terminal of CFP-
10 inhibited binding of the protein complex to the cell surface,
whereas a similar deletion in ESAT-6 had no effect [16]. This
suggests that the C terminus of CFP-10 constitutes the functional
part of the heterodimer and could therefore explain the
preferential binding of the aptamers to CFP-10. In this study
characterisation of the aptamers revealed that the aptamers had
a tight affinity to CFP-10, with the tested aptamers having
dissociation constants in the low nanomolar range.
Figure 5. Binding affinity of the selected ssDNA aptamers to CFP-10 and ESAT-6. Binding of the anti-CFP-10.ESAT-6 biotinylated ssDNA
aptamers to the ESAT-6 and CFP-10 monomers was determined by an ELONA. Binding of the ssDNA aptamers to the CFP-10.ESAT-6 heterodimer is
shown for comparative purposes. Data are presented as means 6 standard deviation of the mean.
doi:10.1371/journal.pone.0046862.g005
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This study used oral cavity bacteria to determine the specificity
of the aptamers. Oral cavity bacteria was chosen due to the wide
diversity of bacteria present that includes gram-positive bacteria,
gram-negative bacteria, anaerobic bacteria, mycobacteria and
fungal species. Lower respiratory tract bacteria are present at
much lower concentrations than oral cavity bacteria and require
the use of specialised techniques such as bronchoscopy [44]. The
bacterial lysate study revealed that the aptamers were able to
recognise S. aureus, M. smegmatis, M. bovis BCG and, in some cases,
P. aeruginosa. This may be due to the fact that M. smegmatis secretes
the CFP-10 protein [45], and although the RD1 region has been
removed from M. bovis BCG, the mycobacterium genome has 23
Figure 6. BIAcore sensogram showing the equilibrium dissociation constantss (KD) of the selected ssDNA apatmers. The binding
kinetics of the ssDNA aptamers to immobilised CFP-10 was determined using BIAcoreH 3000 surface plasmon resonance (SPR). In each case the
aptamer was iinjected over immobolised CFP-10 with an initial concentration at 500 nM, followed by 250 nM, 125 nM, 62 nM and 31 nM.
doi:10.1371/journal.pone.0046862.g006
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ESAT-6 homologues (such as CFP-10, Esx G and Esx H). Thus,
the aptamers might recognise one of theESAT-6-like proteins that
are encoded by one of the other 10 genomic loci [46]. ESAT-6-like
homologues have also been described in the genomes of other
gram-positive bacteria like Bacillus subtilis, B. anthracis, Clostridium
acetobutylicum, Listeria monocytogenes, and S. aureus [47,48]. The
presence of these ESAT-6-like homologues in S. aureusmay explain
why aptamers raised against the CFP-10.ESAT-6 heterodimer also
bind to lysates of S. aureus.
Despite binding of the aptamer to M. smegmatis, M. bovis BCG
and S. aureus, CSIR 2.11 was selected and tested for its ability to
detect TB using sputum samples. CSIR 2.11 had a specificity of
68.75% using Youden’s index, which is lower than that observed
for antibodies raised to detect the CFP-10 monomer [20]. The
sensitivity and specificity of a more specific aptamer, CSIR 2.21,
was not significantly different from that of CSIR 2.11 in
a comparative study using 28 sputum samples. Possible reasons
for some of the false positive readings in this study might be as
a result of S. aureus co-infection [47] or from misclassification bias
due to subclinical TB; however, the patients did not return to the
hospital and thus no further follow up could be done to clarify this
point. Additionally, the lowered specificity may be attributed to
antigen persistence in patients with previous TB infection [49].
Alternatively, long-term persister organisms could be secreting the
culture filtrate proteins at very low levels, detectable by the
aptamers but not by antibodies.
An encouraging aspect of the aptamer-based diagnostic assay, in
this preliminary study, is that it performed reasonably well in both
HIV-infected and HIV-uninfected patients. Further studies, after
appropriate optimisation, will be required in HIV-infected
individuals. Diagnostic tests may vary in their performance in
HIV-infected individuals. GeneXpertH has sub-optimal negative
predictive values in HIV-infected individuals [11], whilst the urine
LAM-assay performs optimally in HIV-infected individuals with
low CD4 counts [50,51]. The sensitivity of the aptamer-based test
is comparable to that of an antibody-based ELISA in a recent
study by Feng et al. [20], with both studies having sensitivities of
over 80% for the detection of CFP-10 in clinical specimens.
Compared to the antibody-based assays, aptamer-based assays
have greater stability under a wide range of conditions, and can be
repeatedly used without losing their binding ability. Aptamers are,
therefore, a promising class of detection reagents for the de-
velopment of improved diagnostics [52]. Moreover, this study, as
well as previous studies have shown that aptamers can be
chemically synthesised, which allows for their rapid production
in large quantities with excellent reproducibility of results
[27,52,53].
Table 1. ELONA results of the ssDNA aptamers tested on different bacterial lysates.
Bacterial Lysate CSIR 2.2 CSIR 2.9 CSIR 2.11 CSIR 2.15 CSIR 2.19 CSIR 2.21
Mycobacterium tuberculosis + + + + + +
Mycobacterium bovis + + + + + –
Mycobacterium smegmatis + – + + + +
Staphylococcus aureus + + + + + –
Pseudomonas aeruginosa – – + + + –
Streptococcus pyogenes – – – – – –
Corynybacterium xerosis – – – – – –
+ positive for CFP-10 detection; 2 negative for CFP-10 detection.
doi:10.1371/journal.pone.0046862.t001
Table 2. ELONA results of the ssDNA aptamer CSIR 2.11 tested as a detection reagent for active TB in sputum samples.






Sputum samples positive for TB 20 20 100% 7 35%
Smear positive, culture positive 15 15 6
Smear negative, culture positive 5 5 1
Specificity Specificity
Sputum samples negative for TB 20 8 68.75% 2 95%
Latent infection 5 2 1
Smear negative, culture negative 15 6 1
Healthy laboratory volunteers negative for TB1 28 7 2
1The two donors who gave a single sample were not detected as TB positive in the ELONA. Of the 13 donors that gave two sputum samples, two cases had both
samples as positive and in three of the cases only the second sample gave a positive reading.
*Youden’s index is one that selects the best trade-off between sensitivity and specificity using a ROC curve, and may not correspond to a cut-point that rules in or rules
out disease.
doi:10.1371/journal.pone.0046862.t002
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Limitations of the current aptamer-based assay are the lack of
a rapid readout, as ELONA takes several hours to complete, as
well as antigenic cross-reactivity. The cross-reactivity of the
aptamer-based assay may be improved through optimisation of
the aptamers, which may include truncation of the current 90-mer
parent aptamers to minimum sequences essential for binding to
the target, which in some cases improves the kinetics of the
aptamers [54]. By truncating the aptamers not only will the cost of
production be reduced, but it may also prevent non-specific
binding. Furthermore, a sandwich assay can be developed that
makes use of two aptamers; one as a capture and the other as
a detector molecule. By making use of such a sandwich assay the
specificity of either the capture or the detector aptamer can be
lower, provided that the combination of the two is highly specific
to the antigen in question.
This study showed that it is feasible to develop aptamers to
relatively TB-specific antigens and thereby detect these antigens in
human biological samples obtained from patients with and without
active TB. However, further optimisation is required to improve
performance outcomes, followed by validation in larger appropri-
ately designed studies using biological samples from different body
compartments. This will lay the foundation for their inclusion and
evaluation in point-of-care detection platforms.
Supporting Information
Figure S1 Expression and purification of CFP-10 and
ESAT-6. (A) SDS analysis of purified CFP-10. Lane 1, Precision
Plus ProteinTM Kaleidoscope Standards (BioRad); and lane 2,
eluate from Ni-NTA column indicating the presence of pure
monomeric CFP-10. (B) Immunoblot analysis of the purified CFP-
10 protein, indicating that the anti-CFP-10 polyclonal antibody
reacted specifically with CFP-10 (lane 1), but not with ESAT-6
(negative control, lane 2). (C) SDS-PAGE analysis of purified
ESAT-6. Lane 1, Precision Plus ProteinTM Kaleidoscope Stan-
dards (BioRad); and lane 2, eluate from Ni-NTA column
indicating the presence of pure monomeric ESTA-6. (D)
Immunoblot analysis of the purified ESAT-6 protein, indicating
that the anti-ESAT-6 monoclonal antibody reacted specifically
with ESAT-6 (lane 1), but not with CFP-10 (negative control, lane
2).
(TIF)
Figure S2 Complex formation by purified recombinant
CFP-10 and ESAT-6 proteins. (A) Native polyacrylamide gel
of purified recombinant ESAT-6 (lane 1) and CFP-10 (lane 2)
proteins, and a mixture of the individual proteins (lane 3). (B)
Confirmation of CFP-10.ESAT-6 complex formation by surface
plasmon resonance (SPR). ESAT-6 was injected on a CFP-10
surface from t0 to t600, followed by removal of unbound ESAT-6
protein. A control experiment was likewise performed on a CM5
sensor chip devoid of CFP-10.
(TIF)
Figure S3 Binding affinity of solid phase-synthesised
ssDNA aptamers. In an ELONA the selected aptamers showed
binding to CFP-10 and CFP-10.ESAT-6, but not to ESAT-6.
These results are in agreement with those presented in Fig. 5,
indicating that chemical synthesis of the aptamers does not
influence their binding ability. Data are presented as means 6
standard deviations of the mean.
(TIF)
Figure S4 Binding of folded and unfolded aptamer CSIR
2.11 to CFP-10. One batch of CSIR 2.11 was refolded and
a second batch was used directly after thawing in the ELONA. No
significant differences were observed in the binding capabilities of
the folded and the unfolded aptamers, indicating that a refolding
step is not necessary for binding of the aptamer to the target
protein. Data are presented as means 6 standard deviation of the
mean.
(TIF)
Figure S5 Binding of selected ssDNA aptamers to
lysates of oral cavity bacteria. An ELONA was used to test
binding of the selected ssDNA aptamers to lysates prepared from
M. tuberculosis, M. smegmatis, M. bovis BCG, P. aeruginosa, S. aureus,
C. xerosis and S. pyogenes.
(TIF)
Figure S6 Evaluation of sputum samples using CSIR
2.11 as a detection reagent. The aptamer was tested on three
groups of samples (A) Definite TB, (B) Latent TB and TB negative
and (C) healthy laboratory volunteers. Using Youden’s index, the
cut-point for positive samples was set at an OD450 of 0.2 and is
indicated by the dotted line. Using the rule-in disease, the cut-
point for positive samples is an OD450 of 0.8 and is demarcated by
the solid line. Data are presented as means 6 standard deviation
of the mean.
(TIF)
Figure S7 Evaluation of sputum samples using a control
aptamer CSIR 3.13 as a detection reagent. Controls
included were an aptamer-alone control, a sputum-alone control,
a positive control (CFP-10 plus CSIR 2.11), as well as sputum
samples that were detected by a ssDNA aptamer (CSIR 3.13) that
was selected using the same library but against a different target.
Data are represented as means6 standard deviation of the means.
(TIF)
Figure S8 Comparison of CSIR 2.11 and CSIR 2.21
using sputum samples. The sensitivity and specificity of CSIR
2.11 and a more specific aptamer, CSIR 2.21, were compared
using 28 sputum samples. Using Youden’s index, the cut-point for
positive samples was set at an OD450 of 0.1 and is indicated by the
solid line. Using the rule-in disease, the cut-point for positive
samples is an OD450 of 0.62 and is demarcated by the dotted line.
Data are presented as means 6 standard deviation of the mean.
Samples that gave a positive result when using CSIR 2.21as
a detection molecule are denoted as CSIR 2.21 positive, while
negative samples are denoted as CSIR 2.21 negative. Samples that
gave a positive result when using CSIR 2.11 as a detection
molecule are denoted as CSIR 2.11 positive, while negative
samples are denoted CSIR 2.11 negative.
(TIF)
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